Potent and selective 5-HT3 receptor antagonist

Serotonin 5-HT3 receptor antagonist

Fluroquinolone antibiotic, suppressing c-Myc transcription and myeloma growth, inhibiting pannexin-1 channels through which ATP is released as find-me signals in apoptotic Jurkat cells

Novel Photosensitive and Photoswitchable TRPA1 Agonist, Optically Control Pain through Channel Desensitization

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

Novel selective inhibitor of the transient receptor potential melastatin 2 (TRPM2) channel, exhibiting TRPM2 selectivity over TRPM8 and TRPV1 channels as well as phospholipase A2 and showing neuroprotective activity in vitro, and significantly reducing ce

Novel agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel

Novel selective TRPV6 inhibitor

Novel TrxR1 inhibitor, selectively killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation

Natural DNA gyrase inhibitor, blocking leukotriene production, inhibiting P-glycoprotein, and showing anti-inflammatory and anti cancer activities

Natural Polycyclic Peptide from a Fungus-Derived Streptomycete

Novel highly selective negative allosteric modulator (NAM) of thyrotropin receptor (TSHR), binding at the ectodomain/TMD interface, between the converging helix, ECL1 and the IA, noncompetitively inhibiting PAM-C2-activation

Novel human thymic stromal lymphopoietin (TSLP) inhibitor

Novel isoform-selective inhibitor of the tumor-associated hCA IX and XII

Novel αvβ3 ligand, disrupting the integrin-MMP2 interaction and showing antiangiogenic activit, inhibiting angiogenesis and tumor growth in vivo

Novel antagonist of T-type calcium channels

First-in-class potent threonine tyrosine kinase (TTK) PROTAC, demonstrating strong TTK degradation in COLO-205 human colorectal cancer cells with DC 50 values of 1.7 nM

First-in-class potent threonine tyrosine kinase (TTK) PROTAC, demonstrating strong TTK degradation in COLO-205 human colorectal cancer cells with DC 50 values of 3.1 nM

Novel transthyretin (TTR) stabilizer, binding to the T4 binding pocket of TTR and preventing the dissociation of TTR to monomer

FLT3 Kinase Inhibitor, Overcoming Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia